Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Keywords

Medicine, Imatinib, Imatinib mesylate, Tyrosine-kinase inhibitor, Tolerability

References

• Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.Philipp le Coutre, Elena Tassi, Marileila Varella‐Garcia — 2000
• High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry.Ray Bakhtiar, Jack J. Lohne, Lourdes Ramos — 2002
• Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteriaStephanie Green, Geoffrey R. Weiss — 1992
• Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.Allan T. van Oosterom, Ian Judson, Jaap Verweij — 2001
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationM. Gorre, Mansoor Mohammed, Katharine Ellwood — 2001
• KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.Marcia L. Lux, Brian P. Rubin, Tara L. Biase — 2000
• Diagnosis of gastrointestinal stromal tumors: A consensus approach.Christopher D.�M. Fletcher, Jules J. Berman, Christopher L. Corless — 2002
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsBrian Druker, Shu Tamura, Elisabeth Buchdunger — 1996
• Gastrointestinal stromal tumors: recent advances in understanding of their biology.Markku Miettinen, Maarit Sarlomo‐Rikala, Jerzy Lasota — 1999
• Gastrointestinal Stromal Tumors, Intramural Leiomyomas, and Leiomyosarcomas in the Duodenum: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 167 CasesMarkku Miettinen, Mary Furlong, Maarit Sarlomo‐Rikala — 2001
• Molecular Insights into the Histogenesis and Pathogenesis of Gastrointestinal Stromal TumorsBrian P. Rubin, Jonathan A. Fletcher, Christopher D.�M. Fletcher — 2000
• STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implicationsDavid A. Tuveson, Nicholas A. Willis, Tyler Jacks — 2001
• KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.Brian P. Rubin, Samuel Singer, C. Tsao — 2001
• Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution.Jason L. Hornick, Christopher D.�M. Fletcher — 2002
• Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.Michael C. Heinrich, Diana Griffith, Brian Druker — 2000
• Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.Elisabeth Buchdunger, Catherine L. Cioffi, Norman M. Law — 2000
• Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.Brian Druker, Charles L. Sawyers, Hagop M. Kantarjian — 2001
• Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.Ronald P. DeMatteo, Jonathan J. Lewis, Denis H. Y. Leung — 2000
• Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.Heikki Joensuu, Peter Roberts‎, Maarit Sarlomo‐Rikala — 2001
• Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571Wenlan Wang, Mary Healy, Martin Sattler — 2000

Cited by

• Gastrointestinal stromal tumors with exon 8 c-kit gene mutation might occur at extragastric sites and have metastasis-prone nature.Takashi Ito, Masahiro Yamamura, Toshihiro Hirai — 2014
• Effects of systemic chemotherapy on the liver.Giuliano Ramadori, Silke Cameron — 2010
• Imatinib (Gleevec)-induced hepatotoxicity.Walid S. Ayoub, Stephen A. Geller, Tram T. Tran — 2005
• Computational and experimental studies of protein kinase-inhibitor interactionsShun Zhu — 2011
• Chemotherapy in soft tissue sarcomaThe Scandinavian Sarcoma Group experienceJ.-O. Fernberg, K. Sundby Hall — 2004
• GIST as the model of paradigm shift towards targeted therapy of solid tumors: update and perspective on trial design.Jaap Verweij, Caroline Seynaeve, Stefan Sleijfer — 2008
• Imatinib MesylateS. Duquerroy — 2012
• Imatinib Attenuates Diabetes-Associated AtherosclerosisKimberly M Green, Bradley George — 2004
• Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.J. María Gallego — 2004
• Plasma and Cerebrospinal Fluid Pharmacokinetics of Imatinib after Administration to Nonhuman Primates哲人 岩國 — 2004
• Targeting other abnormal signaling pathways in sarcoma: EGFR in synovial sarcomas, PPAR-gamma in liposarcomas.Gabriel Figueroa Saavedra — 2004
• Revision of gastrointestinal mesenchymal tumours with CD117.Tae Jun Bae — 2004
• Hypoglycemia in the Setting of Advanced Gastrointestinal Stromal TumorJacfranz J. Guiteau, Michael Fanucchi, Andrew Folpe — 2006
• Primäre Sarkome und Sarkommetastasen in der LeberGunhild Mechtersheimer, Roland Penzel, Wolfgang Hofmann — 2006
• Epithelioid Gastrointestinal Stromal Tumor With PDGFRA Activating Mutation and ImmunoreactivityA.B. Edwards, G.T. Nedelka — 2005
• Effect of Tyrosine Kinase Inhibition Using Imatinib on Normal Lymphohematopoietic CellsMarune Renta Nattassya — 2005
• Tyrosine kinases as targets for cancer therapy.Daniela S. Krause, Richard A. Van Etten — 2005
• Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.明美 日野, たえこ 中村 — 2005
• Advanced gastrointestinal stromal tumor patients with complete response after treatment with imatinib mesylate.Francisco Lencina Gutiérrez, Fernando Albert Rico, Ulrich Aistleitner — 2006
• In vivo effects of imatinib mesylate on human haematopoietic progenitor cellsAndré Vant — 2006

Related papers

• Treatment of gastrointestinal stromal tumor after imatinib and sunitinibMichael Montemurro, Sebastian Bauer — 2011
• Sunitinib versus imatinib dose escalation after failure of imatinib standard dose in patients with advanced Gastrointestinal stromal tumors – a real-world multi-center studyShaoqing Huang, Xing Liu, Xiaodan Guo — 2023
• Dose optimization of tyrosine kinase inhibitors to improve outcomes in GISTJohn Zalcberg, Jayesh Desai — 2012
• Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): Case reportIn Keun Choi, Byung‐Soo Kim, Kyung‐A Lee — 2004
• Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia.Franziska Michor — 2007
• Simultaneously occurring chronic myelogenous leukemia and gastrointestinal stromal tumors treated with imatinibYuji Mishima, Y. Terui, Kengo Takeuchi — 2006
• Analysis of onset mechanism for tyrosine kinase inhibitor imatinib induced-left ventricular diastolic dysfunctionKoki Chiba, Mihoko Hagiwara-Nagasawa, Ryuichi Kambayashi — 2020
• Gleevec: The Sequel2004
• Are All Multi-targeted Tyrosine Kinase Inhibitors Created Equal? An In Vitro Study of Sunitinib and Pazopanib in Renal Cell Carcinoma Cell LinesDaniel Canter, Alexander Kutikov, Konstantin Golovine — 2011
• Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemiasElias Jabbour, Samih El Ahdab, Jörge E. Cortes — 2008